Patents Assigned to ABBVIE STEMCENTRX LLC
  • NOVEL ANTI-MFI2 ANTIBODIES AND METHODS OF USE
    Publication number: 20170320960
    Abstract: Provided are novel anti-MFI2 antibodies and antibody drug conjugates, and methods of using such anti-MFI2 anti-bodies and antibody drug conjugates to treat cancer.
    Type: Application
    Filed: September 4, 2015
    Publication date: November 9, 2017
    Applicant: ABBVIE STEMCENTRX LLC
    Inventors: SAMUEL WILLIAMS, LAURA SAUNDERS, HOLGER KARSUNKY, MANDY BOONTANRART
  • KITS CONTAINING DLL3 ANTIBODY DRUG CONJUGATES
    Publication number: 20170307622
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
    Type: Application
    Filed: June 7, 2017
    Publication date: October 26, 2017
    Applicant: ABBVIE STEMCENTRX LLC
    Inventors: ROBERT A. STULL, LAURA SAUNDERS, SCOTT J. DYLLA, ORIT FOORD, DAVID LIU, MICHAEL TORGOV, HUI SHAO
  • Anti-DLL3 antibody drug conjugates for treating cancer
    Patent number: 9775916
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
    Type: Grant
    Filed: May 30, 2017
    Date of Patent: October 3, 2017
    Assignee: AbbVie Stemcentrx LLC
    Inventors: Robert A. Stull, Laura Saunders, Scott J. Dylla, Orit Foord, David Liu, Michael Torgov, Hui Shao
  • Anti-PTK7 antibody-drug conjugates
    Patent number: 9777070
    Abstract: The present invention provides anti-PTK7 antibody-drug conjugates and methods for preparing and using the same.
    Type: Grant
    Filed: April 27, 2015
    Date of Patent: October 3, 2017
    Assignees: PFIZER INC, ABBVIE STEMCENTRX LLC
    Inventors: Marc Isaac Damelin, Puja Sapra, Alexander John Bankovich, Scott J. Dylla
  • Anti-DPEP3 antibodies and methods of use
    Patent number: 9777071
    Abstract: Provided herein are novel anti-DPEP3 antibodies and antibody drug conjugates (ADC), including derivatives thereof, and methods of using the same to treat proliferative disorders.
    Type: Grant
    Filed: October 21, 2016
    Date of Patent: October 3, 2017
    Assignee: ABBVIE STEMCENTRX LLC
    Inventors: Laura Saunders, Deepti Rokkam, David Liu, Mandy Boontanrart
  • Identification and enrichment of cell subpopulations
    Patent number: 9778264
    Abstract: Markers useful for the identification, characterization and, optionally, the enrichment or isolation of tumorigenic cells or cell subpopulations are disclosed.
    Type: Grant
    Filed: August 7, 2014
    Date of Patent: October 3, 2017
    Assignee: ABBVIE STEMCENTRX LLC
    Inventors: Scott J. Dylla, Marianne Santaguida, Wade C. Anderson, Bob Y. Liu, Samuel A. Williams
  • DLL3 MODULATORS AND METHODS OF USE
    Publication number: 20170274094
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
    Type: Application
    Filed: June 7, 2017
    Publication date: September 28, 2017
    Applicant: ABBVIE STEMCENTRX LLC
    Inventors: ROBERT A. STULL, LAURA SAUNDERS, SCOTT J. DYLLA, ORIT FOORD, DAVID LIU, MICHAEL TORGOV, HUI SHAO
  • Anti-DLL3 antibody drug conjugates
    Patent number: 9770518
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
    Type: Grant
    Filed: May 30, 2017
    Date of Patent: September 26, 2017
    Assignee: AbbVie Stemcentrx LLC
    Inventors: Robert A. Stull, Laura Saunders, Scott J. Dylla, Orit Foord, David Liu, Michael Torgov, Hui Shao
  • METHODS OF DELIVERING DLL3 ANTIBODY DRUG CONJUGATES
    Publication number: 20170266313
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
    Type: Application
    Filed: May 30, 2017
    Publication date: September 21, 2017
    Applicant: ABBVIE STEMCENTRX LLC
    Inventors: ROBERT A. STULL, LAURA SAUNDERS, SCOTT J. DYLLA, ORIT FOORD, DAVID LIU, MICHAEL TORGOV, HUI SHAO
  • ANTI-DLL3 ANTIBODY DRUG CONJUGATES
    Publication number: 20170266312
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
    Type: Application
    Filed: May 30, 2017
    Publication date: September 21, 2017
    Applicant: ABBVIE STEMCENTRX LLC
    Inventors: ROBERT A. STULL, LAURA SAUNDERS, SCOTT J. DYLLA, ORIT FOORD, DAVID LIU, MICHAEL TORGOV, HUI SHAO
  • ANTI-DLL3 ANTIBODY DRUG CONJUGATES FOR TREATING CANCER
    Publication number: 20170266315
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
    Type: Application
    Filed: May 30, 2017
    Publication date: September 21, 2017
    Applicant: ABBVIE STEMCENTRX LLC
    Inventors: ROBERT A. STULL, LAURA SAUNDERS, SCOTT J. DYLLA, ORIT FOORD, DAVID LIU, MICHAEL TORGOV, HUI SHAO
  • METHODS OF MAKING DLL3 ANTIBODY DRUG CONJUGATES
    Publication number: 20170266314
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
    Type: Application
    Filed: May 30, 2017
    Publication date: September 21, 2017
    Applicant: ABBVIE STEMCENTRX LLC
    Inventors: ROBERT A. STULL, LAURA SAUNDERS, SCOTT J. DYLLA, ORIT FOORD, DAVID LIU, MICHAEL TORGOV, HUI SHAO
  • Modulators and methods of use
    Patent number: 9765136
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of such modulators to treat hyperproliferative disorders are provided.
    Type: Grant
    Filed: March 17, 2016
    Date of Patent: September 19, 2017
    Assignee: AbbVie Stemcentrx LLC
    Inventors: Johannes Hampl, Scott J. Dylla, Orit Foord, Robert A. Stull
  • Methods of making DLL3 antibody drug conjugates
    Patent number: 9764042
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
    Type: Grant
    Filed: May 30, 2017
    Date of Patent: September 19, 2017
    Assignee: AbbVie Stemcentrx LLC
    Inventors: Robert A. Stull, Laura Saunders, Scott J. Dylla, Orit Foord, David Liu, Michael Torgov, Hui Shao
  • Anti SEZ6 antibodies and methods of use
    Patent number: 9676850
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
    Type: Grant
    Filed: February 22, 2013
    Date of Patent: June 13, 2017
    Assignee: ABBVIE STEMCENTRX LLC
    Inventors: Laura Saunders, Scott J. Dylla, Orit Foord, Robert A. Stull, Michael Torgov, Hui Shao, David Liu
  • ANTI-DLL3 ANTIBODIES AND DRUG CONJUGATES FOR USE IN MELANOMA
    Publication number: 20170137533
    Abstract: Anti-DLL3 antibodies and antibody drug conjugates for use in the diagnosis and treatment of melanoma.
    Type: Application
    Filed: February 23, 2015
    Publication date: May 18, 2017
    Applicant: AbbVie Stemcentrx LLC
    Inventors: Samuel WILLIAMS, Laura SAUNDERS, Kathryn A LOVING
  • ANTI-CD324 MONOCLONAL ANTIBODIES AND USES THEREOF
    Publication number: 20170121416
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
    Type: Application
    Filed: November 16, 2016
    Publication date: May 4, 2017
    Applicant: ABBVIE STEMCENTRX LLC
    Inventors: Robert A. STULL, Monette AUJAY, Orit FOORD, Alex BANKOVICH, Johannes HAMPL, Scott J. DYLLA, David LIU
  • NOVEL MODULATORS AND METHODS OF USE
    Publication number: 20170081419
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat hyperproliferative disorders are provided.
    Type: Application
    Filed: August 29, 2016
    Publication date: March 23, 2017
    Applicant: AbbVie Stemcentrx LLC
    Inventors: Scott J. Dylla, Orit Foord, Robert A. Stull, Wade C. Anderson, Saiyou Ohshima
  • NOVEL ANTI-RNF43 ANTIBODIES AND METHODS OF USE
    Publication number: 20170073430
    Abstract: The invention discloses novel anti-RNF43 antibodies and derivatives thereof, including antibody drug conjugates, and methods of using such anti-RNF43 antibodies and antibody drug conjugates to diagnose and treat cancer.
    Type: Application
    Filed: April 21, 2015
    Publication date: March 16, 2017
    Applicant: AbbVie Stemcentrx LLC
    Inventors: MANDY BOONTANRART, DEEPTI ROKKAM, DAVID LIU, SCOTT J. DYLLA, MONETTE AUJAY
  • NOVEL ANTI-DPEP3 ANTIBODIES AND METHODS OF USE
    Publication number: 20170044271
    Abstract: Provided herein are novel anti-DPEP3 antibodies and antibody drug conjugates (ADC), including derivatives thereof, and methods of using the same to treat proliferative disorders.
    Type: Application
    Filed: October 21, 2016
    Publication date: February 16, 2017
    Applicant: AbbVie Stemcentrx LLC
    Inventors: LAURA SAUNDERS, DEEPTI ROKKAM, DAVID LIU, MANDY BOONTANRART